Exagen Inc. (XGN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Exagen Inc. (XGN) Healthcare & Pipeline Overview

Exagen Inc. pioneers diagnostic solutions for autoimmune diseases, leveraging its AVISE technology to provide rheumatologists with tools for improved diagnosis and patient management. With a focus on connective tissue diseases, Exagen addresses a critical need in the healthcare sector, though profitability remains a challenge.

What Is the Investment Thesis for XGN?

Exagen Inc. presents a focused investment opportunity within the autoimmune diagnostics space. The company's AVISE branded tests cater to a critical need for rheumatologists, offering tools for diagnosing and monitoring complex conditions like lupus and rheumatoid arthritis. With a gross margin of 58.3%, Exagen demonstrates strong pricing power. Growth catalysts include expanding the adoption of AVISE CTD and other specialized tests, as well as potential breakthroughs from their research collaboration with Allegheny Health Network (AHN). However, the company's negative profit margin of -30.0% and high beta of 1.94 indicate significant financial risk and market volatility. Investors should closely monitor Exagen's ability to improve profitability and manage its operating expenses.

Based on FMP financials and quantitative analysis

XGN Key Highlights

Market Cap of $170M reflects its small-cap status and potential for growth, but also higher volatility.

• Gross Margin of 58.3% indicates strong pricing power in its diagnostic testing services.
• Profit Margin of -30.0% highlights the company's current unprofitability and need for improved cost management.
• Beta of 1.94 suggests the stock is significantly more volatile than the overall market.
• Focus on autoimmune disease diagnostics positions Exagen in a growing market with unmet needs.

Who Are XGN's Competitors?

XGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XGN's Key Strengths?

Proprietary CB-CAPs technology

• AVISE branded tests with established clinical utility
• Focus on specialized diagnostic testing for autoimmune diseases
• Research collaboration with Allegheny Health Network (AHN) Research Institute

What Are XGN's Weaknesses?

Negative profit margin

• High beta indicating significant market volatility
• Reliance on a limited number of products
• Small market capitalization

What Could Drive XGN Stock Higher?

Data releases from ongoing clinical studies evaluating the clinical utility of AVISE tests.

• Potential FDA approvals for new diagnostic tests developed in collaboration with AHN.
• Expansion of sales and marketing efforts to increase adoption of AVISE CTD and other specialized tests.
• Securing favorable reimbursement decisions from payers for AVISE branded tests.

What Are the Key Risks for XGN?

Financial-distress signal — its Altman Z-Score of -4.82 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established diagnostic companies with greater resources.
• Reimbursement challenges and changes in healthcare policies.
• Failure to successfully develop and commercialize new diagnostic tests.
• Dependence on a limited number of products and customers.

What Are the Growth Opportunities for XGN?

• Expanding AVISE CTD Adoption: AVISE CTD is Exagen's lead testing product, offering differential diagnosis for connective tissue diseases. Increasing its adoption among rheumatologists represents a significant growth opportunity. The market for CTD diagnostics is substantial, driven by the complexity of these diseases and the need for accurate and timely diagnosis. Exagen can expand its market share through targeted marketing, educational programs, and partnerships with healthcare providers. Success hinges on demonstrating the clinical utility and cost-effectiveness of AVISE CTD.
• Commercializing AVISE Lupus and APS: AVISE Lupus and AVISE APS address the diagnostic and management needs for systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), respectively. These tests offer valuable insights into disease activity and potential complications. The market for SLE and APS diagnostics is growing, driven by increasing awareness and improved treatment options. Exagen can capitalize on this trend by expanding its sales force, conducting clinical studies, and securing favorable reimbursement for these tests. Success depends on demonstrating the clinical value and cost-effectiveness of AVISE Lupus and APS.
• Developing Novel Biomarkers: Exagen's research collaboration with Allegheny Health Network (AHN) Research Institute focuses on developing novel biomarkers for autoimmune diseases. This collaboration has the potential to yield breakthrough diagnostic and prognostic tools. The market for novel biomarkers is substantial, driven by the need for more precise and personalized medicine. Exagen can leverage this collaboration to expand its product portfolio and gain a competitive advantage. Success depends on the successful identification, validation, and commercialization of these biomarkers.
• Expanding into New Geographic Markets: Exagen currently focuses on the United States market. Expanding into new geographic markets, such as Europe and Asia, represents a significant growth opportunity. The global market for autoimmune disease diagnostics is substantial, driven by increasing prevalence and improved healthcare infrastructure. Exagen can leverage its existing technology and expertise to enter these markets through partnerships, acquisitions, or direct sales. Success depends on adapting its products and marketing strategies to local market conditions.
• Securing Favorable Reimbursement: Reimbursement policies play a critical role in the adoption of diagnostic tests. Securing favorable reimbursement for its AVISE branded tests is essential for Exagen's growth. The market for reimbursed diagnostic tests is substantial, driven by the need for affordable and accessible healthcare. Exagen can work with payers, healthcare providers, and patient advocacy groups to demonstrate the clinical value and cost-effectiveness of its tests. Success depends on navigating the complex reimbursement landscape and securing favorable coverage decisions.

What Are XGN's Competitive Advantages?

• Proprietary CB-CAPs technology
• AVISE branded tests with established clinical utility
• Research collaboration with Allegheny Health Network (AHN) Research Institute
• Focus on specialized diagnostic testing for autoimmune diseases

What Does XGN Do?

Exagen Inc., founded in 2002 and headquartered in Vista, California, is a diagnostics company focused on autoimmune diseases. Originally named Exagen Diagnostics, Inc., the company rebranded in January 2019 to Exagen Inc. The company develops and commercializes testing products based on its cell-bound complement activation products (CB-CAPs) technology under the AVISE brand. These tests enable rheumatologists to diagnose, prognose, and monitor autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Exagen's lead product, AVISE CTD, aids in the differential diagnosis of patients presenting with symptoms indicative of various connective tissue diseases (CTDs). Other key offerings include AVISE Lupus, which measures complement system activation, and AVISE APS, a panel of autoantibody tests for diagnosing and managing antiphospholipid syndrome (APS). The company also provides specialized tests like AVISE SLE Prognostic, AVISE Vasculitis AAV, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor, AVISE MTX, and AVISE HCQ. Exagen collaborates with Allegheny Health Network (AHN) Research Institute to develop novel biomarkers, enhancing its diagnostic capabilities.

What Products and Services Does XGN Offer?

• Develop and commercialize diagnostic testing products.
• Focus on autoimmune and autoimmune-related diseases.
• Offer AVISE CTD for differential diagnosis of connective tissue diseases.
• Provide AVISE Lupus for measuring complement system activation.
• Offer AVISE APS for diagnosing and managing antiphospholipid syndrome.
• Develop specialized tests like AVISE SLE Prognostic and AVISE Vasculitis AAV.
• Collaborate with Allegheny Health Network (AHN) Research Institute to develop novel biomarkers.

How Does XGN Make Money?

• Generate revenue through the sale of diagnostic testing services.
• Focus on direct sales to rheumatologists and healthcare providers.
• Secure reimbursement from payers for its AVISE branded tests.
• Collaborate with research institutions to develop new products and technologies.

What Industry Does XGN Operate In?

Exagen Inc. operates within the medical diagnostics and research industry, a segment experiencing growth driven by increasing prevalence of autoimmune diseases and advancements in diagnostic technologies. The market is competitive, with established players and emerging companies vying for market share. Exagen differentiates itself through its CB-CAPs technology and specialized AVISE tests. The industry is also influenced by regulatory requirements, reimbursement policies, and technological innovations. Exagen's success depends on its ability to innovate, secure favorable reimbursement, and effectively market its diagnostic solutions to rheumatologists and healthcare providers.

Who Are XGN's Key Customers?

• Rheumatologists
• Healthcare providers
• Patients with autoimmune diseases
• Hospitals and clinics

Exagen Inc. Financial Trajectory

Exagen Inc. (XGN) reported $19.9M in revenue for Q2 FY2026, reflecting 15.2% growth compared to the prior quarter. The company recorded a net loss of $3.2M, with diluted EPS of $-0.13. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, XGN averaged $-0.21 in diluted EPS.

Company Profile

Exagen Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Vista, US. The company is led by CEO John Aballi. XGN has traded publicly since 2019.

How Exagen Inc. Is Valued

Exagen Inc. carries a market capitalization of $170M, placing it in the micro-cap category. Analyst price targets span from $8.00 to $10.00, with a consensus of $8.50. At the current price of $7.03, that implies approximately 21% upside potential. Relative to its peer group, XGN's quantitative score of 20/100 is below the peer average of 58/100.

Key Financial Metrics

Return on assets is -36.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.3%, the inverse of the P/E and a quick read on earnings relative to price.

Exagen Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.82 places it in the distress zone, a signal of elevated financial risk.

Exagen Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses.

Over the past six months, Exagen Inc. insiders filed 8 SEC Form 4 transactions — 1 sales and 7 purchases. On net that is roughly 206K shares acquired (about $826K) — insiders putting money in tends to read as conviction.

XGN Financials

XGN Latest News

XGN Analyst Consensus

XGN MoonshotScore

Exagen Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources